Research

A multifactorial approach gene therapy for Alzheimer's disease

Our gene therapy is based on E2F4, a promising approach for a disease affecting 50 million people worldwide, with no effective treatment

Tetraneuron is a Spanish biotechnology company focused on gene therapy for brain and neurodegenerative diseases

Headquartered in Madrid and Valencia, Tetraneuron emerges as a spin-off from the Cajal Institute, affiliated with the Spanish National Research Council (CSIC)

Committed to scientific excellence and ethics throughout every stage of the process

The science behind our therapy

Tetraneuron, a pioneer in innovative therapies, has developed a groundbreaking strategy focused on E2F4DN, a patented molecule that mimics the functions of E2F4. What makes this molecule so crucial? E2F4 is a transcription factor that plays a pivotal role in multiple specific networks in humans, particularly in neurodegenerative diseases.
This innovative approach centers on a deep comprehension of neuronal physiology and cellular quiescence, offering solutions for a broad range of neurodegenerative diseases.

Studies carried out by the Tetraneuron team have unveiled that, under certain pathological conditions, the protein E2F4 undergoes a phosphorylation process that disrupts its normal function. This is where our therapy, based on the neuronal expression of E2F4DN, a functional variant of E2F4, comes into play, aimed at restoring cellular function.
At Tetraneuron, we are dedicated to bridging this innovative science from the lab to clinical practice, aiming to create a more hopeful future for patients impacted by neurodegenerative diseases.

Research areas

Tetraneuron’s research is centered around E2F4, a protein involved in regulating various brain pathways

Alzheimer's Disease

Biomarkers

Neurodegenerative diseases

Alzheimer's Disease

Biomarkers

Neurodegenerative diseases

Research papers

Loading...

E2F4DN Transgenic Mice: A Tool for the Evaluation of E2F4 as a Therapeutic Target in Neuropathology and Brain Aging (2022)

A Mutant Variant of E2F4 Triggers Multifactorial Therapeutic Effects in 5xFAD Mice (2022)

E2F4 as a single multifactorial target against Alzheimer’s disease (2021)

E2F4-Based Gene Therapy Mitigates the Phenotype of the Alzheimer’s Disease Mouse Model 5xFAD (2021)

Pathological aspects of neuronal hyperploidization in Alzheimer’s disease evidenced by computer simulation (2020)

Cell cycle reentry triggers hyperploidization and synaptic dysfunction followed by delayed cell death in differentiated cortical neurons (2018)

Neuronal tetraploidization in the cerebral cortex correlates with reduced cognition in mice and precedes and recapitulates Alzheimer’s-associated neuropathology (2017)

Neuronal tetraploidy in Alzheimer and Aging (2017)

Nerve Growth Factor-Induced Cell Cycle Reentry in Newborn Neurons Is Triggered by p38MAPK-Dependent E2F4 Phosphorylation (2012)

Collaborations

We have close collaborations with prominent scientific institutions in the field of neurodegenerative diseases. These partnerships allow us to tap into a broad network of knowledge and resources to advance research and develop cutting-edge therapies.

R&D Projects

From the beginning, Tetraneuron has been engaged in several high-value-added research projects

INDUSTRIAL PHD CAM Program

Tetraneuron has been granted support by the Madrid regional Goverment for an Industrial Doctorate from 2023 to 2026

GeroE2F4DN

The project ‘E2F4DN as a gerotherapeutic agent for brain aging’ (GeroE2F4DN), funded by the Ministry of Science and Innovation within the scope of grants for projects in strategic lines, part of the state plan for scientific, technical, and innovation research 2021-2023, under the recovery, transformation, and resilience plan 2022, aims to evaluate E2F4DN as a gerotherapeutic agent

PIDICV-2022

The project with file number IMIDTA/2022/77 entitled “Characterization of new tools for studying the efficacy of gene therapies against glaucoma,” with a total budget of €145,730, has received a grant of €65,578.50.

This initiative, focused on enhancing knowledge about this condition, marks a new path forward for Tetraneuron in the development of innovative gene therapies for neurodegenerative diseases.

INDUSTRIAL DOCTORATES

Tetraneuron has been granted support for the completion of an Industrial Doctorate under the project “Therapeutic Potential of E2F4DN in Alzheimer’s Disease: Analysis of its Neuroimmunomodulatory Effect”